Novo Nordisk (CPSE:NOVO B) is back in focus after launching its Wegovy pill in Germany, the first EU market to offer the oral weight loss treatment, putting its GLP-1 obesity ambitions under closer investor scrutiny. <\/p>\n
The stock has been under pressure despite Novo Nordisk’s obesity pipeline progress, with a 30 day share price return of 4.16%, a year to date share price return decline of 11.05%, and a 1 year total shareholder return down 14.14%. This suggests momentum has faded recently after earlier gains. <\/p>\n
Scan beyond Novo Nordisk and consider other obesity and healthcare opportunities with solid fundamentals in our hand picked list of solid balance sheet and fundamentals (437 results)<\/a>. <\/p>\n Novo Nordisk now trades below its recent highs while pushing ahead with Wegovy and share buybacks. Is that a chance to add exposure today, or a setup that rewards patience for a clearer entry later as valuation comes into focus? <\/p>\n Most Popular Narrative: 65.5% Undervalued <\/p>\n According to the most followed narrative on Novo Nordisk, a fair value of DKK851.04 sits well above the last close of DKK293.75, which puts the current share price firmly in the discount zone and makes the assumptions behind that gap worth understanding. <\/p>\n Novo Nordisk has built a formidable economic moat (“Burggraben”) through decades of expertise in diabetes care, world-class manufacturing, and a trusted global brand. With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform. This windfall is now driving massive capital inflows, which Novo Nordisk is wisely reinvesting to secure its leadership for decades to come. <\/p>\n Read the complete narrative.<\/a> <\/p>\n Want to see why this narrative pushes Novo Nordisk so far above today’s DKK293.75 price? The valuation leans heavily on robust margins, sustained revenue growth and a richer future earnings multiple. Curious how these ingredients combine to reach DKK851.04 without stretching the discount rate assumptions? <\/p>\n Result: Fair Value of DKK851.04 (UNDERVALUED) <\/p>\n Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n However, this upbeat Novo Nordisk story could be challenged if GLP-1 competition tightens pricing faster than expected or if manufacturing expansion stumbles and constrains supply. <\/p>\n Find out about the key risks to this Novo Nordisk narrative.<\/a> <\/p>\n Next Steps <\/p>\n With Novo Nordisk pulled between clear risks and appealing rewards, it makes sense to move quickly and weigh the evidence yourself. To see how those trade offs show up in the data, review the 3 key rewards and 2 important warning signs<\/a>. <\/p>\n Looking for more investment ideas beyond Novo Nordisk? <\/p>\n If Novo Nordisk has caught your attention, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that fit your risk and return goals. <\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (CPSE:NOVO B) is back in focus after launching its Wegovy pill in Germany, the first EU…\n","protected":false},"author":2,"featured_media":157318,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[3335,272,52701,1910],"class_list":["post-157317","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-glp-1","tag-novo-nordisk","tag-novo-nordisks","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117197848332752765","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/157317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=157317"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/157317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/157318"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=157317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=157317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=157317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}